studi
activ
rna
cell
particular
rna
interfer
virus
revolution
understand
mani
role
play
macromolecul
discoveri
rna
replic
also
possess
catalyt
activ
suggest
singl
macromolecul
could
origin
carri
replic
inform
catalysi
viral
sequenc
genom
variou
organ
unexpect
amount
virus
phage
biospher
suggest
virus
help
build
genom
drive
evolut
articl
deal
contrast
effect
avian
paramyxoviru
newcastl
diseas
viru
ndv
exert
differ
speci
like
bird
mice
human
tri
answer
question
possibl
viru
pathogen
bird
benefici
effect
mous
tumor
cancer
patient
recognit
noncap
viral
leader
rna
cytoplasm
ndv
infect
human
cell
retinoicacidinduc
gene
rigi
initi
strong
type
interferon
ifn
respons
good
exampl
interact
anoth
exampl
recent
identifi
host
cellderiv
microrna
target
rigi
mrna
degrad
escap
mechan
type
interferon
respons
describ
prerequisit
ndv
replic
avian
cell
ebola
viru
ebov
replic
human
cell
review
give
overview
characterist
molecular
biolog
ndv
describ
interest
immunobiolog
aspect
includ
oncolysi
immunogen
cell
death
icd
main
part
summar
year
clinic
applic
ndv
cancer
patient
includ
success
viru
product
accord
good
manufactur
practic
gmp
revers
genet
ndv
dealt
provid
molecular
basi
genet
engin
exampl
newli
engin
recombin
ndv
viral
vector
protect
new
emerg
viru
diseas
given
approxim
million
year
evolut
virus
mammal
deriv
therapsid
time
adapt
immun
system
host
exemplifi
later
ebov
devast
pathogen
man
major
bird
speci
develop
approxim
million
year
ago
accord
recent
wholegenom
analysi
thu
comparison
mammal
bird
virus
appear
shorter
period
adapt
bird
immun
system
ndv
avian
paramyxoviru
type
caus
seriou
diseas
chicken
bird
known
nd
ndv
outbreak
first
report
indonesia
subsequ
newcastleupontyn
uk
year
sever
panzoot
diseas
poultri
domest
pigeon
last
four
decad
effort
control
diseas
involv
develop
new
vaccin
vaccin
protocol
sinc
ndv
consid
use
laboratori
viru
replic
virul
studi
recent
summar
ndv
strain
classifi
velogen
mesogen
lentogen
accord
pathotyp
virul
velogen
strain
highli
infecti
bird
viscerotrop
neurotrop
pathotyp
introduc
avian
popul
ndv
rapidli
transmit
among
suscept
bird
either
inhal
ingest
viru
spread
rapidli
premis
movement
appar
healthi
infect
bird
movement
peopl
contamin
equip
food
water
airborn
spread
one
premis
anoth
gener
sign
nd
includ
depress
loss
appetit
abnorm
thirst
sever
dehydr
emaci
fever
mortal
reach
mesogen
strain
ndv
usual
caus
respiratori
diseas
adult
chicken
lentogen
strain
pathogen
first
contact
viru
permiss
host
occur
respiratori
epitheli
cell
viral
attach
mediat
hemagglutininneuraminidas
protein
hn
protein
bind
gangliosid
nglycoprotein
contain
distinct
structur
sialic
acid
sugar
viru
cell
bind
follow
activ
viral
fusion
protein
f
fusion
viral
host
cell
membran
allow
transfer
viral
genom
host
cell
cytoplasm
kb
nonseg
neg
singlestrand
rna
ssrna
transcrib
mrna
translat
viral
protein
embryon
chicken
egg
ece
univers
use
viru
isol
presenc
viru
allanto
fluid
determin
hemagglutin
ha
test
hemagglutin
inhibit
hi
test
commonli
use
identifi
ndv
addit
panel
monoclon
antibodi
use
character
group
isol
three
vivo
test
use
assess
pathogen
ndv
isol
perform
either
ninedayold
egg
onedayold
chick
sixweekold
chicken
current
world
organ
anim
health
use
two
paramet
differenti
virul
isol
notifi
diseas
avirul
isol
notifi
sinc
convent
vivo
pathogen
test
time
consum
expens
sever
rapid
phenotyp
method
base
revers
transcript
rt
pcr
develop
assay
realtim
rtpcr
rrtpcr
offer
highest
sensit
ndv
sensit
heat
min
lipid
solvent
ionic
nonion
deterg
formaldehyd
oxid
agent
due
rna
natur
genom
viru
sensit
uv
irradi
resist
ndv
virion
nm
diamet
pleomorph
mostli
spheric
shape
virion
envelop
lipid
membran
host
cell
plasma
membran
envelop
contain
two
transmembran
hn
fusion
f
protein
protein
present
homooligom
form
spikelik
project
nm
length
outer
surfac
envelop
beneath
envelop
lie
nonglycosyl
membran
protein
call
matrix
protein
insid
virion
particl
rest
nucleocapsid
classic
herringbon
morpholog
diamet
nm
viral
nucleocapsid
consist
singl
speci
viral
rna
nucleotid
nt
length
replicon
complex
nucleocapsid
n
phosphoprotein
p
larg
polymeras
protein
l
ndv
produc
ece
also
cell
cultur
often
produc
human
tumor
cell
line
good
manufactur
practic
gmp
product
advis
use
avian
embryon
establish
cell
line
follow
standard
oper
procedur
sop
valid
asept
oper
grade
b
area
first
step
consist
creat
master
cell
bank
mcb
follow
establish
master
seed
viru
msv
viru
seed
stock
mvss
qualif
msv
involv
titrat
via
determin
tissu
cultur
infect
activ
identif
sequenc
proof
absenc
adventiti
non
viral
viral
agent
next
step
consist
establish
ndv
manufactur
process
bioreactor
involv
upstream
downstream
process
batch
certifi
releas
batch
specif
releas
criteria
fulfil
achiev
worldwid
first
time
iozk
germani
complet
genom
sequenc
mani
strain
ndv
avail
web
wwwncbinlmnihgov
base
complet
genom
sequenc
phylogenet
tree
design
codonassoci
rate
chang
six
ndv
protein
reveal
highest
rate
chang
occur
fusion
protein
genom
size
ndv
consist
rule
six
characterist
rule
thought
aris
need
fulli
encapsid
entir
length
genom
chain
n
protein
monom
span
exactli
nt
prevent
digest
rna
nucleas
genom
rna
contain
nt
region
known
leader
nt
region
known
trailer
leader
trailer
control
region
essenti
transcript
replic
also
encapsid
newli
synthes
rna
viru
particl
flank
six
gene
viral
genom
ndv
genom
carri
code
sequenc
transcript
begin
singl
promot
present
leader
region
first
leader
rna
nt
synthes
follow
sequenti
transcript
gene
order
yield
individu
mrna
stopstart
mechan
guid
conserv
genestart
geneend
signal
genestart
initi
synthesi
mrna
geneend
direct
polyadenyl
termin
mrna
leader
rna
neither
cap
polyadenyl
function
mrna
mrna
cap
methyl
polyadenyl
viral
polymeras
incorpor
two
g
nucleotid
rna
edit
site
p
protein
result
frameshift
variant
protein
v
v
accessori
protein
involv
antagon
avian
cellular
antivir
respons
infect
v
interact
speciesspecif
fashion
bird
cell
protein
inhibit
ifn
signal
lead
degrad
signal
transduc
activ
transcript
inhibit
induct
new
method
infecti
virus
gener
entir
clone
dna
cdna
abil
recov
negativestrand
rna
virus
includ
ndv
cdna
clone
allow
investig
structur
function
individu
viral
gene
protein
revers
genet
technolog
also
enabl
design
recombin
live
ndv
vaccin
vaccin
vector
suitabl
cell
line
transfect
plasmid
express
fulllength
antigenom
rna
cotransfect
three
support
plasmid
encod
viral
n
p
l
control
bacteriophag
rna
polymeras
promot
recoveri
recombin
ndv
requir
activ
rna
polymeras
enzym
provid
recombin
vaccinia
viru
express
gene
cell
line
constitut
express
polymeras
detail
contain
two
recent
review
replic
life
cycl
rna
virus
involv
format
doublestrand
rna
dsrna
foreign
structur
activ
import
cellular
defenc
system
base
type
interferon
mutat
tumor
cell
often
crippl
interferon
system
allow
uninhibit
cell
prolifer
provid
rel
resist
apoptosi
nonpermiss
host
mutat
make
tumor
cell
rel
permiss
substrat
replic
rna
virus
ndv
identifi
mechan
explain
tumor
select
viral
replic
oncolysi
nonpermiss
host
involv
defect
activ
antivir
signal
pathway
ii
defect
type
ifn
signal
pathway
iii
defect
apoptot
pathway
iv
activ
ra
signal
express
protein
infect
cell
ndv
involv
basic
two
step
cell
bind
membran
fusion
transduct
viral
genom
transcript
viral
gene
viral
replic
use
newli
produc
nucleocapsid
antigenom
infect
normal
cell
nonpermiss
host
usual
proceed
second
step
contrast
nearli
test
humanmurin
tumor
cell
transform
cell
ndv
infect
proceed
second
step
thu
allow
tumor
select
replic
ndv
abil
replic
faster
human
cancer
cell
normal
human
cell
ndv
number
desir
properti
make
attract
oncolyt
agent
nonpermiss
avian
host
mous
man
known
enter
cell
bind
sialic
acid
residu
present
human
cancer
cell
make
suitabl
use
broad
rang
cancer
cell
type
ndv
fast
grow
viru
highli
fusogen
tumor
cell
virtual
preexist
immun
ndv
gener
human
popul
import
new
paradigm
oncolyt
virusmedi
immunotherapi
concept
immunogen
cell
death
icd
classic
physiolog
apoptosi
nonimmunogen
featur
icd
induc
ndv
tumor
cell
includ
endoplasmat
reticulum
er
stress
respons
immunogen
apoptosi
necrosi
autophagi
icd
featur
lead
shutdown
protein
synthesi
surfac
exposur
calreticulin
heatshock
protein
hsp
viral
protein
hn
f
upregul
major
histocompat
class
protein
mhc
adhes
molecul
lead
improv
antigen
present
immunogen
apoptosi
select
recruit
neutrophil
first
innat
immun
respond
infect
ndv
caus
releas
neutrophil
attract
chemokin
neutrophil
recruit
chemokin
seem
old
evolutionari
conserv
mechan
across
vertebr
sinc
chemokin
evolv
million
year
ago
fish
pathogenassoci
molecular
pattern
pamp
ndv
recogn
respect
pattern
recognit
receptor
prr
innat
immun
cell
viral
leader
rna
ii
dsrna
iii
hn
protein
pamp
recogn
respect
follow
prr
cytoplasm
rigi
ii
cytoplasm
dsrna
depend
protein
kinas
r
pkr
endosom
tolllik
receptor
tlr
iii
plasma
membran
express
nk
cell
receptor
prr
initi
multipl
respons
pathway
lead
strong
type
interferon
respons
releas
proinflammatori
cytokin
activ
immun
cell
final
cell
necrosi
lead
releas
damageassoci
molecular
pattern
damp
cytokin
chemokin
orthotop
murin
glioma
model
demonstr
ndv
virotherapi
induc
icd
molecular
determin
calreticulin
hsp
high
mobil
group
amphoterin
follow
tumorspecif
immun
cell
memori
viral
surfac
protein
hn
shown
recogn
prr
murin
nk
cell
transmit
cytotox
induc
signal
transfect
cell
surfac
expos
hn
f
molecul
induc
paracrin
stimul
assay
human
peripher
blood
mononuclear
cell
pbmc
cell
surfac
express
tnfrelat
apoptosisinduc
ligand
trail
secret
upon
contact
ndv
nk
cell
also
monocyt
becom
activ
produc
tumoricid
activ
trail
ndv
infect
macrophag
produc
nitric
oxid
via
activ
nuclear
factorkappa
b
effect
ndv
human
dendrit
cell
dc
studi
sophist
way
use
technolog
develop
system
biolog
due
avian
origin
ndv
consid
prototyp
viru
studi
uninhibit
cellular
respons
human
dc
antivir
state
transit
dc
occur
within
h
postinfect
ndv
chang
genet
program
explain
regulatori
network
distinct
transcript
factor
tf
regul
express
upregul
gene
antivir
state
transit
associ
polar
dc
toward
type
type
polar
favor
induct
helper
type
cell
respons
upon
antigen
present
dc
genet
reprogram
dc
ndv
justifi
term
prime
usual
associ
cell
adapt
immun
respons
b
lymphocyt
regard
cell
hn
molecul
surfac
infect
tumor
cell
shown
introduc
new
cell
adhes
strength
interact
lymphocyt
tcell
costimul
includ
helper
cytotox
cell
ndv
induc
human
pbmc
dc
monocyt
strong
type
ifn
respons
occur
within
h
consist
earli
phase
late
phase
earli
phase
initi
recognit
pamp
prr
see
section
signal
transduct
cascad
nucleu
induc
first
follow
late
phase
ifn
respons
induc
secret
molecul
interact
cell
surfac
express
type
ifn
receptor
ifnra
initi
amplif
loop
ifn
respons
involv
stat
protein
interferon
regulatori
factor
murin
studi
associ
describ
strength
type
interferon
respons
resist
cell
normal
neoplast
viru
replic
follow
infect
ndv
studi
reveal
import
role
ifn
respons
rigi
addit
studi
cell
knockout
mice
devoid
gene
ifnra
show
import
receptor
absenc
normal
cell
incap
prevent
ndv
replic
type
interferon
demonstr
import
gener
cytotox
lymphocyt
ctl
respons
vivo
low
basic
level
ifn
constitut
express
follow
applic
neutral
antiifn
antibodi
mice
imposs
induc
ctl
precursor
cell
addit
vitro
ctl
restimul
cultur
addit
neutral
antiifn
antibodi
inhibit
ctl
respons
augment
tumorspecif
ctl
respons
observ
mice
immun
ndv
infect
tumor
cell
comparison
mice
immun
noninfect
tumor
cell
mediat
via
result
immun
cell
cooper
intranas
applic
ndv
mice
induc
lung
epitheli
cell
proinflammatori
cytokin
type
interferon
import
also
counteract
regulatori
cell
treg
activ
immun
escap
type
interferon
respons
permiss
ndv
infect
avian
cell
mediat
via
v
protein
frameshift
variant
viral
phosphoprotein
p
v
inhibit
ifn
signal
target
degrad
also
inhibit
induct
interact
melanoma
differentiationassoci
gene
lead
inhibit
activ
v
protein
show
specif
avian
protein
interfer
ifn
respons
mammalian
cell
ebola
viru
ebov
primat
evolut
develop
immun
escap
mechan
type
ifn
respons
primat
cell
ebov
first
discov
belong
largest
known
rna
virus
diamet
nm
length
nm
member
filovirida
famili
similar
ndv
genom
ebov
consist
neg
ssrna
code
protein
two
eight
viral
protein
involv
immunosuppress
antagonis
earli
phase
interferon
responseit
bind
directli
dsrna
inhibit
antivir
signal
also
block
viru
induc
phosphoryl
prevent
dimer
nuclear
transloc
cell
express
also
observ
suppress
phosphoryl
pkr
elong
initi
factor
contrast
antagonist
late
phase
bind
directli
inhibit
nuclear
transloc
tabl
summar
describ
molecular
determin
rna
viral
immun
stimul
ndv
man
rna
viral
immun
escap
ndv
bird
ebola
man
intratumor
intraperiton
inject
oncolyt
ndv
mesogen
attenu
strain
caus
durabl
complet
tumor
regress
athym
mice
bear
human
neuroblastoma
fibrosarcoma
xenograft
recombin
ndv
strain
deriv
velogen
strain
italien
intratumor
inject
induc
syncytium
format
cell
death
also
prolong
surviv
tumorbear
athym
mice
suppress
loss
bodi
weight
orthotop
glioma
studi
immunocompet
syngen
mice
reveal
intratumor
virotherapi
ndv
induc
icd
longterm
surviv
induc
protect
immun
depend
function
adapt
immun
system
cell
latter
recent
result
corrobor
earlier
find
postop
antitumor
vaccin
murin
esb
lymphoma
model
autolog
ndv
infect
tumor
cell
vaccin
induc
immun
includ
th
ctl
highli
specif
protect
outgrowth
metastas
increas
significantli
percentag
longterm
surviv
mice
antitumor
effect
ndv
also
expect
nonavian
vertebr
speci
case
tumor
domest
anim
cat
dog
anim
veterinari
medicin
like
hors
pig
cow
anoth
area
futur
ndv
applic
ndv
capac
replic
nonprolifer
tumor
cell
xirradi
tumor
vaccin
cell
sinc
viru
replic
cytoplasm
independ
cell
prolifer
oncolyt
ndv
potenti
target
tumor
stem
cell
cell
tumor
dormanc
may
affect
chemo
radiotherapi
furthermor
ndv
replic
apoptosisresist
tumor
cell
hypox
cancer
cell
interferonresist
tumor
cell
resist
immunotherapi
also
broken
ndv
infect
human
cell
toler
melanoma
could
broken
melanoma
infect
ndv
strain
ulster
mous
melanoma
model
local
oncolyt
ndv
virotherapi
demonstr
overcom
system
tumor
resist
immun
checkpoint
blockad
immunotherapi
import
suggest
result
clinic
applic
immun
checkpoint
blockad
immunotherapi
improv
combin
oncolyt
ndv
liver
fibrosi
major
health
problem
common
caus
death
unit
state
activ
hepat
stellat
cell
hesc
crucial
factor
respons
liver
fibrosi
hesc
liverresid
bone
marrow
deriv
mesenchym
stem
cell
locat
space
diss
store
total
bodi
vitamin
upon
activ
star
shape
hesc
differenti
myofibroblast
produc
extracellular
matrix
ecm
thu
contribut
liver
fibrosi
ndv
inject
hepat
fibrosi
mice
regress
liver
fibrosi
observ
replic
ndv
murin
primari
hesc
human
hesc
cell
demonstr
coloc
ndv
muscl
actin
viru
infect
reduc
product
collagen
fibril
matrix
metalloproteinas
mmp
viru
replic
hesc
follow
cell
death
via
apoptosi
consid
import
liver
fibrosi
connect
hepatocellular
carcinoma
hcc
find
strong
potenti
clinic
impact
number
ndv
strain
use
prevent
vaccin
nd
poultri
industri
vaccin
perform
use
either
live
inactiv
vaccin
mass
applic
live
vaccin
spray
aerosol
popular
sever
lentogen
strain
lasota
use
year
proven
track
record
safeti
efficaci
howev
complet
prevent
infect
viru
shed
also
possess
genet
marker
allow
differenti
infect
vaccin
bird
recent
recombin
nd
vaccin
innovaxnd
approv
us
fda
commerci
use
recent
also
shown
attenu
genotyp
vii
ndv
vaccin
gener
revers
genet
effect
protect
vaccin
bird
homolog
virul
genotyp
vii
viru
challeng
reduc
viru
shed
significantli
lasota
vaccin
anim
although
known
arm
immun
respons
viral
envelop
glycoprotein
import
provid
protect
nd
known
robust
immun
respons
requir
complet
ceas
viru
replic
provid
longterm
protect
like
induc
envelop
glycoprotein
particip
innat
adapt
cell
mediat
humor
immun
respons
certain
type
virus
oncolyt
andor
antineoplast
properti
use
virotherapi
cancer
patient
advantag
exist
use
oncolyt
paramyxovirus
comparison
virus
famili
eg
retrovirus
dna
virus
lack
gene
exchang
via
recombin
lack
interact
host
cell
dna
even
rel
high
dose
ndv
well
toler
cancer
patient
report
side
effect
mild
grade
common
mild
fever
placebocontrol
phase
ii
clinic
trial
perform
csatari
hungari
includ
latestag
cancer
patient
ndv
treatment
group
placebo
group
use
attenu
oncolyt
veterinari
vaccin
strain
mukteswar
term
viru
appli
via
inhal
target
lung
metastas
four
thousand
infecti
unitsday
ndv
inhal
twice
weekli
six
month
clinic
result
suggest
decreas
cancerrel
symptom
better
surviv
howev
disput
studi
random
consist
heterogen
group
patient
csatari
group
later
report
select
case
seri
studi
four
highgrad
glioma
treat
studi
show
radiographicallydocu
respons
long
surviv
improv
symptomatolog
anoth
oncolyt
ndv
strain
test
patient
advanc
cancer
phase
trial
conduct
unit
state
patient
n
given
escal
dose
viru
intraven
tumor
respond
convent
therapi
dose
three
billion
infecti
particl
well
toler
doselimit
toxic
includ
dyspnea
dehydr
diarrhea
patient
desensit
lower
initi
dose
maxim
toler
dose
increas
suggest
prime
precondit
effect
immun
system
see
section
section
cassel
atlanta
ga
usa
report
earli
ndv
oncolyt
strain
antineoplast
agent
observ
develop
postoncolyt
antitumor
immun
focus
develop
viral
oncolys
vaccin
use
vaccin
postop
manag
malign
melanoma
patient
vaccin
perform
mani
year
never
stop
complet
detail
phase
ii
clinic
studi
involv
patient
stage
ii
metastat
melanoma
ajcc
stage
iii
summar
cassel
conclud
result
unusu
diseasefre
surviv
period
includ
except
surviv
patient
head
neck
diseas
six
case
cerebr
metastas
suggest
uniqu
role
administr
ndv
oncolys
manag
stage
ii
melanoma
patient
group
german
cancer
research
center
dkfz
heidelberg
establish
anim
model
system
studi
cancer
metastasi
immunotherapi
concept
use
live
cell
ndv
infect
tumor
cell
vaccin
rather
oncolys
live
cell
vaccin
appar
higher
immunogen
lysat
vaccin
term
atvndv
consist
million
irradi
tumor
cell
infect
ndv
lentogen
strain
ulster
antimetastat
effect
observ
preclin
studi
specif
protect
immun
induc
mechan
function
summar
elsewher
translat
research
mous
man
perform
seri
test
human
tumor
cell
line
tumor
cell
fresh
oper
specimen
develop
protocol
produc
human
atvndv
vaccin
pleiotrop
immun
stimulatori
properti
type
vaccin
phase
ii
clinic
postop
vaccin
studi
perform
patient
differ
type
cancer
year
trial
involv
among
other
carcinoma
breast
colon
rectum
kidney
head
neck
pancrea
glioblastoma
multiform
gbm
two
studi
summar
patient
suffer
gbm
n
vaccin
atvndv
cell
cultur
assess
feasibl
safeti
clinic
benefit
phase
studi
median
progressionfre
surviv
pf
vaccin
patient
week
vs
week
nonvaccin
control
subject
time
period
clinic
median
overal
surviv
os
week
vs
week
control
subject
p
vaccin
group
immun
monitor
reveal
signific
increas
skin
antitumor
delayedtyp
hypersensit
dth
reactiv
number
tumorreact
memori
cell
mtc
blood
number
tumorinfiltr
lymphocyt
til
frozen
tissu
slice
gbm
recurr
one
complet
remiss
nonresect
tumor
mass
ii
prospect
random
phase
iiiii
trial
investig
effici
atvndv
liver
resect
hepat
metastas
colorect
carcinoma
crc
tertiari
prevent
method
stage
iv
crc
patient
n
vaccin
compar
similar
number
nonvaccin
compar
patient
except
long
followup
period
ten
year
end
signific
differ
vaccin
control
arm
howev
stratifi
tumor
local
clearcut
differ
colon
rectum
signific
benefit
seen
colon
rectum
cancer
subgroup
term
longterm
metastasisfre
surviv
os
colon
cancer
control
arm
die
vaccin
arm
latter
trial
corrobor
similar
result
increas
os
obtain
studi
sinc
latter
studi
perform
prospect
random
phase
iiiii
studi
provid
clinic
evid
effect
potenti
cancer
vaccin
atvndv
potenti
mechan
function
longterm
surviv
observ
stage
iv
colon
carcinoma
patient
describ
detail
import
role
longterm
surviv
associ
cancerreact
mtc
prime
tumorassoci
antigen
taa
cancer
patient
either
spontan
upon
antitumor
vaccin
bone
marrow
demonstr
prime
site
tcell
respons
bloodborn
taa
patientderiv
reactiv
mtc
bone
marrow
upon
transfer
nodscid
mice
bear
autolog
human
tumor
xenotranspl
capabl
tumor
reject
thu
demonstr
import
tabl
summar
variou
mention
antitumor
effect
ndv
mous
man
spite
promis
result
gener
new
idea
improv
appear
necessari
consid
fact
still
major
patient
consid
nonrespond
immunotherapi
ndvbase
tumor
vaccin
one
strategi
improv
consist
augment
tcell
costimulatori
signal
achiev
attach
atvndv
ndvspecif
singl
chain
antibodi
dual
specif
bispecif
bs
antibodi
fusion
protein
instanc
crc
patient
latestag
diseas
could
longer
subject
surgeri
cur
intent
n
treat
sever
advers
event
notic
phase
trial
vaccin
none
patient
detect
level
tumorreact
blood
circulatori
mtc
patient
show
immunolog
respons
tumorreact
mtc
least
cours
five
vaccin
addit
doserespons
relationship
costimulatori
molecul
attach
vaccin
partial
respons
metastas
decreas
recist
criteria
document
four
patient
strategi
improv
combin
viral
oncolys
vol
atvndv
dendrit
cell
dc
volpuls
dc
voldc
develop
immunolog
oncolog
center
iozk
cologn
germani
idea
meant
improv
de
novo
gener
taaspecif
cell
cell
iozk
receiv
offici
permit
individu
applic
advanc
therapeut
medicin
product
atmp
cancer
patient
new
strategi
cancer
immunotherapi
iozk
consist
combin
hyperthermia
oncolyt
viru
pretreat
specif
autolog
antitumor
vaccin
hyperthermia
activ
immun
system
adjust
reach
tissu
temperatur
system
oncolyt
ndv
viru
pretreat
posit
precondit
effect
see
section
section
patient
immun
system
induc
volreact
helper
cell
creat
system
recal
respons
site
voldc
vaccin
induc
chemokin
therebi
enhanc
dc
migrat
drain
lymph
node
improv
antitumor
efficaci
vitro
helper
cell
increas
matur
human
dc
much
better
matur
stimuli
one
casereport
iozk
demonstr
longterm
remiss
prostat
cancer
patient
extens
bone
metastas
patient
fail
standard
therapi
treatment
induc
longlast
tumorreact
mtc
respons
anoth
case
report
relat
longterm
surviv
breast
cancer
patient
extens
liver
metastas
oper
patient
refus
standard
therapi
instead
treat
strategi
iozk
patient
surviv
month
initi
diagnosi
addit
continu
high
qualiti
life
report
new
result
iozk
relat
case
seri
studi
gbm
patient
kaplanmei
surviv
analysi
newli
diagnos
oper
patient
show
median
overal
surviv
os
month
compar
month
standard
radiochemotherapi
accord
stupp
protocol
remark
also
surviv
current
seri
combinatori
immunotherapi
almost
research
topic
address
recent
ebook
frontier
oncolog
oncolyt
virus
ov
har
combin
agent
mediat
stronger
antitumor
effect
among
other
follow
strategi
propos
discuss
combin
ov
immun
checkpoint
block
antibodi
ii
combin
ov
hyperthermia
iii
combin
ov
activ
cell
iv
combin
ov
approv
drug
novel
small
molecul
dampen
innat
adapt
antivir
respons
increas
antitumor
immun
respons
v
combin
ov
chemotherapi
pharmaceut
immunomodul
snf
vi
improv
tumor
target
specif
efficaci
system
tumor
target
ndv
could
improv
use
bispecif
adapt
protein
also
reduc
unwant
sideeffect
tumor
target
graft
cell
could
becom
improv
via
cellbound
trispecif
antibodi
direct
tumorintroduc
viral
antigen
hn
ndv
applic
plasmid
encod
hn
protein
ndv
phn
ear
pinna
mice
induc
high
level
system
reduc
tumor
growth
tumor
bear
mice
vaccin
phn
dna
compar
control
dna
caus
signific
increas
nk
cell
infiltr
decreas
infiltr
myeloidderiv
suppressor
cell
mdsc
recent
studi
underlin
potenti
recombin
ndv
recndv
vaccin
vector
express
level
foreign
protein
influenza
viru
hemagglutinin
high
foreign
gene
stabl
mani
viru
passag
vitro
vivo
recndv
engin
even
two
gene
secret
full
intact
antibodi
respect
heavi
light
chain
igg
hybridoma
incorpor
viral
genom
new
virus
variant
caus
epidem
pose
huge
public
health
problem
econom
loss
within
short
time
ndvbase
live
attenu
vaccin
complet
protect
chicken
mice
lethal
challeng
homolog
heterolog
avian
influenza
virus
similar
result
obtain
recndv
engin
express
spike
glycoprotein
sever
acut
respiratori
syndrom
coronaviru
sarscov
intranas
immun
vaccin
protect
african
green
monkey
challeng
high
dose
sarscov
viru
ndv
seem
particularli
suit
vector
respiratori
viral
infect
ndv
may
employ
agent
immun
stimul
prophylact
condit
host
immun
system
risk
viral
infect
see
section
section
section
may
particularli
relev
individu
come
contact
patient
infect
instanc
ebov
recndv
engin
express
ebov
viral
antigen
could
well
suit
prophylact
vaccin
would
express
hn
adjuv
stimul
strong
type
interferon
respons
well
target
antigen
ebov
viruslik
particl
also
activ
type
interferon
pathway
shown
facilit
postexposur
protect
ebov
acanthamoeba
polyphaga
mimiviru
apmv
isol
amoeba
hospit
investig
pneumonia
outbreak
studi
interact
apmv
human
cell
reveal
viru
abl
evad
ifn
system
inhibit
regul
interferonstimul
gene
suggest
viru
human
interact
anoth
exampl
recndv
vector
might
futur
becom
useful
tabl
contain
futur
strategi
har
oncolyt
virusmedi
antitumor
immun
use
ndv
vector
new
emerg
viru
diseas
much
learn
avian
rna
viru
ndv
viru
capabl
evolut
adapt
immun
system
bird
gener
frameshift
variant
protein
v
interfer
type
interferon
respons
cell
bird
emerg
virus
caus
fatal
diseas
man
ebola
develop
similar
viral
interferon
escap
mechan
revers
genet
technolog
enabl
develop
ndv
vector
incorpor
foreign
gene
vector
capabl
protect
instanc
chicken
avian
influenza
viru
african
green
monkey
sarscov
viru
tumor
cell
somat
mutat
often
develop
mechan
escap
growth
inhibit
effect
type
interferon
nonpermiss
host
mous
human
allow
avian
viru
ndv
replic
select
tumor
cell
exert
oncolyt
effect
regard
medic
applic
ndv
cancer
patient
follow
immunobiolog
mechan
import
oncolyt
ndv
destroy
tumor
cell
induc
cell
death
immunogen
initi
direct
antitumor
cell
respons
lead
destruct
tumor
cell
develop
tumorreact
memori
cell
latter
play
import
role
longterm
surviv
addit
ndv
potenti
break
variou
type
therapi
resist
find
explain
promis
effect
seen
oncolyt
ndv
ndvbase
vaccin
eg
atvndv
voldc
cancer
patient
iozk
cologn
germani
first
place
voldc
atmp
appli
offici
permit
futur
ndv
would
becom
includ
protocol
standard
treatment
mani
cancer
patient
would
abl
profit
hitherto
ndv
fulfil
mani
prerequisit
new
therapeut
drug
man
high
safeti
profil
low
side
effect
comparison
chemo
radiotherapi
manyfold
antineoplast
effect
strong
type
ifn
respons
broad
immunostimulatori
effect
review
ndv
variou
applic
viral
vaccin
poultri
ii
recombin
vector
emerg
pathogen
iii
ov
immun
stimul
cancer
patient
good
reason
expect
mani
benefit
research
applic
ndv
